GB201901306D0 - Multi-domain binding molecules - Google Patents

Multi-domain binding molecules

Info

Publication number
GB201901306D0
GB201901306D0 GBGB1901306.9A GB201901306A GB201901306D0 GB 201901306 D0 GB201901306 D0 GB 201901306D0 GB 201901306 A GB201901306 A GB 201901306A GB 201901306 D0 GB201901306 D0 GB 201901306D0
Authority
GB
United Kingdom
Prior art keywords
binding molecules
domain binding
domain
molecules
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1901306.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunocore Ltd
Original Assignee
Immunocore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunocore Ltd filed Critical Immunocore Ltd
Priority to GBGB1901306.9A priority Critical patent/GB201901306D0/en
Publication of GB201901306D0 publication Critical patent/GB201901306D0/en
Priority to PCT/EP2020/052316 priority patent/WO2020157211A1/en
Priority to US17/427,581 priority patent/US20220119479A1/en
Priority to KR1020217026912A priority patent/KR20210121120A/ko
Priority to CN202080012052.4A priority patent/CN113474367A/zh
Priority to MX2021009274A priority patent/MX2021009274A/es
Priority to JP2021544405A priority patent/JP2022523722A/ja
Priority to EP20703193.1A priority patent/EP3917955A1/en
Priority to BR112021014962-7A priority patent/BR112021014962A2/pt
Priority to CA3126628A priority patent/CA3126628A1/en
Priority to AU2020213907A priority patent/AU2020213907A1/en
Priority to IL284891A priority patent/IL284891A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1901306.9A 2019-01-30 2019-01-30 Multi-domain binding molecules Ceased GB201901306D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB1901306.9A GB201901306D0 (en) 2019-01-30 2019-01-30 Multi-domain binding molecules
AU2020213907A AU2020213907A1 (en) 2019-01-30 2020-01-30 Half-life extended ImmTAC binding CD3 and a HLA-A*02 restricted peptide
CN202080012052.4A CN113474367A (zh) 2019-01-30 2020-01-30 结合cd3和hla-a*02限制性肽的半衰期延长的immtac
US17/427,581 US20220119479A1 (en) 2019-01-30 2020-01-30 Half-life extended immtac binding cd3 and a hla-a*02 restricted peptide
KR1020217026912A KR20210121120A (ko) 2019-01-30 2020-01-30 반감기 연장된 immtac 결합 cd3 및 hla-a*02 제한 펩티드
PCT/EP2020/052316 WO2020157211A1 (en) 2019-01-30 2020-01-30 Half-life extended immtac binding cd3 and a hla-a*02 restricted peptide
MX2021009274A MX2021009274A (es) 2019-01-30 2020-01-30 Moleculas de union a multiples dominios.
JP2021544405A JP2022523722A (ja) 2019-01-30 2020-01-30 複数ドメイン結合性分子
EP20703193.1A EP3917955A1 (en) 2019-01-30 2020-01-30 Half-life extended immtac binding cd3 and a hla-a*02 restricted peptide
BR112021014962-7A BR112021014962A2 (pt) 2019-01-30 2020-01-30 Moléculas de ligação de múltiplos domínios, composição farmacêutica, ácido nucleico, vetor de expressão, célula hospedeira, método de produção da molécula de ligação de múltiplos domínios, e método de tratamento
CA3126628A CA3126628A1 (en) 2019-01-30 2020-01-30 Half-life extended immtac binding cd3 and a hla-a*02 restricted peptide
IL284891A IL284891A (en) 2019-01-30 2021-07-15 An HLA-A 02 and CD3-restricted peptide binds IMMTAC with an extended half-life

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1901306.9A GB201901306D0 (en) 2019-01-30 2019-01-30 Multi-domain binding molecules

Publications (1)

Publication Number Publication Date
GB201901306D0 true GB201901306D0 (en) 2019-03-20

Family

ID=65997844

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1901306.9A Ceased GB201901306D0 (en) 2019-01-30 2019-01-30 Multi-domain binding molecules

Country Status (12)

Country Link
US (1) US20220119479A1 (ko)
EP (1) EP3917955A1 (ko)
JP (1) JP2022523722A (ko)
KR (1) KR20210121120A (ko)
CN (1) CN113474367A (ko)
AU (1) AU2020213907A1 (ko)
BR (1) BR112021014962A2 (ko)
CA (1) CA3126628A1 (ko)
GB (1) GB201901306D0 (ko)
IL (1) IL284891A (ko)
MX (1) MX2021009274A (ko)
WO (1) WO2020157211A1 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
WO2022184805A1 (en) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
AU2022233285A1 (en) 2021-03-09 2023-10-19 Cdr-Life Ag Mage-a4 peptide-mhc antigen binding proteins
EP4198052A1 (en) 2021-12-15 2023-06-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptides and antigen binding proteins for use in immunotherapy against fibrolamellar hepatocellular carcinoma (fl-hcc) and other cancers
IL314832A (en) 2022-02-20 2024-10-01 Immunocore Ltd TCR and HIV-specific binding molecules
WO2024038165A1 (en) * 2022-08-18 2024-02-22 Immunocore Ltd T cell receptor fusion proteins specific for mage a4
WO2024038183A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024038193A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024038198A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0977886A4 (en) 1997-03-07 2002-10-23 Sunol Molecular Corp FUSION PROTEINS, WHICH CONTAIN A BACTERIOPHAGE ENVELOPE PROTEIN AND A SINGLE CHAIN T-CELL RECEPTOR
KR100712256B1 (ko) 1997-10-02 2007-04-27 알토 바이오사이언스 코포레이션 가용성 단일쇄 ｔ-세포 수용체 단백질
AU2001232204A1 (en) 2000-02-22 2001-09-03 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
PL208712B1 (pl) 2001-08-31 2011-05-31 Avidex Ltd Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
GB0227351D0 (en) * 2002-11-22 2002-12-31 Isis Innovation Soluble T-cell receptors
JP5563194B2 (ja) 2004-06-29 2014-07-30 イムノコア リミテッド 改変ｔ細胞レセプターを発現する細胞
EP2172484A3 (en) 2005-05-18 2010-05-19 Ablynx N.V. Serum albumin binding proteins
US8512873B2 (en) 2008-07-22 2013-08-20 Furukawa Electric Co., Ltd. Surface treated copper foil and copper clad laminate
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
WO2013041865A1 (en) 2011-09-22 2013-03-28 Immunocore Limited T cell receptors
GB201522592D0 (en) 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
RS63371B1 (sr) 2016-04-08 2022-08-31 Immunocore Ltd T ćelijski receptori
CN109952319B (zh) * 2016-06-02 2023-08-25 英美偌科有限公司 对gp100具有特异性的TCR-抗CD3 scFv融合蛋白的定量用药方案
US11274157B2 (en) * 2017-01-12 2022-03-15 Eureka Therapeutics, Inc. Constructs targeting histone H3 peptide/MHC complexes and uses thereof
GB201709866D0 (en) * 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors
CN112424230A (zh) * 2018-05-14 2021-02-26 英美偌科有限公司 双功能结合多肽

Also Published As

Publication number Publication date
MX2021009274A (es) 2021-08-24
EP3917955A1 (en) 2021-12-08
CA3126628A1 (en) 2020-08-06
CN113474367A (zh) 2021-10-01
US20220119479A1 (en) 2022-04-21
IL284891A (en) 2021-08-31
AU2020213907A1 (en) 2021-09-09
JP2022523722A (ja) 2022-04-26
WO2020157211A1 (en) 2020-08-06
BR112021014962A2 (pt) 2021-09-28
KR20210121120A (ko) 2021-10-07

Similar Documents

Publication Publication Date Title
GB201901306D0 (en) Multi-domain binding molecules
IL281901A (en) Multivalent binding compounds based on IgM and IgA-Fc
IL273631A (en) Special hpv molecules bind
IL289867A (en) Immunostimulatory multisegmented binding compounds
GB201612520D0 (en) Binding molecules
IL287555A (en) binding compounds
IL288314A (en) Anti-tdp-43 binding molecules and uses thereof
GB201702091D0 (en) Specific binding molecules
GB201901305D0 (en) Specific binding molecules
GB201811410D0 (en) OX40 Binding molecules
IL289415A (en) Claudin-6 binding molecules and their use
IL292119A (en) conjugated molecules
IL286013A (en) cd3 binding molecules
GB201811408D0 (en) CD137 Binding Molecules
IL289266A (en) new molecules
IL288561A (en) gal9-binding molecules with immunosuppressive activity
EP3781204A4 (en) BINDING MOLECULES
GB201915282D0 (en) Specific binding molecules
IL269752B (en) fgfr3 binding molecules
IL288562A (en) Activating gal9 binding molecules
GB201803178D0 (en) Specific binding molecules for htert
GB201906118D0 (en) Anti-LAG-3 binding molecules
GB202010329D0 (en) Specific binding molecules
GB202006629D0 (en) Specific binding molecules
GB201914468D0 (en) Binding Molecules

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)